Penobscot Investment Management Company Inc. Has $3.98 Million Stock Position in Intuitive Surgical, Inc. $ISRG

Penobscot Investment Management Company Inc. lifted its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 146.7% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 7,325 shares of the medical equipment provider’s stock after buying an additional 4,356 shares during the quarter. Penobscot Investment Management Company Inc.’s holdings in Intuitive Surgical were worth $3,981,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of the company. AMF Tjanstepension AB lifted its stake in shares of Intuitive Surgical by 120.8% in the second quarter. AMF Tjanstepension AB now owns 147,796 shares of the medical equipment provider’s stock worth $80,314,000 after buying an additional 80,873 shares during the last quarter. Sava Infond d.o.o. raised its stake in Intuitive Surgical by 0.9% during the 2nd quarter. Sava Infond d.o.o. now owns 8,970 shares of the medical equipment provider’s stock valued at $4,874,000 after purchasing an additional 80 shares during the last quarter. LGT Fund Management Co Ltd. raised its stake in Intuitive Surgical by 98.9% during the 2nd quarter. LGT Fund Management Co Ltd. now owns 3,063 shares of the medical equipment provider’s stock valued at $1,664,000 after purchasing an additional 1,523 shares during the last quarter. Apexium Financial LP raised its stake in Intuitive Surgical by 6.8% during the 2nd quarter. Apexium Financial LP now owns 504 shares of the medical equipment provider’s stock valued at $274,000 after purchasing an additional 32 shares during the last quarter. Finally, Quent Capital LLC raised its stake in Intuitive Surgical by 5.5% during the 2nd quarter. Quent Capital LLC now owns 1,428 shares of the medical equipment provider’s stock valued at $776,000 after purchasing an additional 74 shares during the last quarter. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Intuitive Surgical Stock Performance

Shares of Intuitive Surgical stock opened at $452.35 on Friday. The firm’s 50-day simple moving average is $463.55 and its 200-day simple moving average is $500.00. Intuitive Surgical, Inc. has a twelve month low of $425.00 and a twelve month high of $616.00. The firm has a market cap of $162.16 billion, a P/E ratio of 63.09, a price-to-earnings-growth ratio of 4.64 and a beta of 1.61.

Intuitive Surgical (NASDAQ:ISRG) last posted its earnings results on Tuesday, July 22nd. The medical equipment provider reported $2.19 earnings per share for the quarter, topping the consensus estimate of $1.93 by $0.26. Intuitive Surgical had a net margin of 28.51% and a return on equity of 14.56%. The business had revenue of $2.44 billion for the quarter, compared to analyst estimates of $2.35 billion. During the same quarter in the prior year, the firm earned $1.78 EPS. The firm’s quarterly revenue was up 21.4% compared to the same quarter last year. On average, equities analysts forecast that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current fiscal year.

Insider Transactions at Intuitive Surgical

In other news, insider Gary S. Guthart sold 29,360 shares of the company’s stock in a transaction dated Friday, August 29th. The shares were sold at an average price of $472.49, for a total value of $13,872,306.40. Following the sale, the insider owned 19,827 shares of the company’s stock, valued at approximately $9,368,059.23. This represents a 59.69% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Myriam Curet sold 4,500 shares of the company’s stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $492.48, for a total transaction of $2,216,160.00. Following the completion of the sale, the executive vice president directly owned 353 shares in the company, valued at approximately $173,845.44. The trade was a 92.73% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 45,224 shares of company stock valued at $21,716,492. 0.70% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several equities analysts recently commented on ISRG shares. Evercore ISI upped their target price on shares of Intuitive Surgical from $470.00 to $550.00 and gave the company an “in-line” rating in a research note on Tuesday, July 8th. Wall Street Zen upgraded shares of Intuitive Surgical from a “hold” rating to a “buy” rating in a research note on Saturday. Wells Fargo & Company upped their target price on shares of Intuitive Surgical from $559.00 to $599.00 and gave the company an “overweight” rating in a research note on Wednesday, July 23rd. Zacks Research cut shares of Intuitive Surgical from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 20th. Finally, Truist Financial upped their target price on shares of Intuitive Surgical from $590.00 to $600.00 and gave the company a “buy” rating in a research note on Wednesday, July 23rd. Fourteen equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $594.19.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.